Titan Prime Titan Prime, an inflatable penile prosthesis (IPP), will be available in the U.S. in late 2026. The global leader within intimate healthcare today announced FDA approval of Titan...
MIDDLETOWN, Conn., June 03, 2026 (GLOBE NEWSWIRE) -- Vital Nutrients, a practitioner-founded nutritional supplement company, introduces Vital Nutrients Kids, a...
Independent, Peer-Reviewed Study Demonstrated Significant Improvement in Patient Outcomes, Reduction in Over 350 Nursing Hours in Year One, and 20%...
Independent, Peer-Reviewed Study Demonstrated Significant Improvement in Patient Outcomes, Reduction in Over 350 Nursing Hours in Year One, and 20%...
AeroRemote Insights productivity dashboard AeroRemote Insights Productivity dashboard provides total exams by location, site and technologist, and then breaks down...
AeroRemote Insights productivity dashboard AeroRemote Insights Productivity dashboard provides total exams by location, site and technologist, and then breaks down...
CAMBRIDGE, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a...
All Evaluable Patients Achieved Improvements in Multiple Hallmarks of MYBPC3-Associated HCM Benefits Among Cohort 1 Patients Sustained as Far Out as...
HOUSTON, June 03, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued...
Also Announces Marketing Program VANCOUVER, BC / ACCESS Newswire / June 2, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H) (WKN: A3EKSZ)...
– 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended...
Gedatolisib plus fulvestrant and palbociclib (the “gedatolisib-triplet”) reduced the risk of disease progression or death by 50% vs. alpelisib plus...
Peer reviewed publication details pivotal data, demonstrating 30% improvement in disease-free survival (DFS) in patients with localized prostate cancer undergoing...
ALISO VIEJO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company,...
No Clinical Safety or Efficacy Concerns Currently Identified Agency Feedback Primarily Focused on CMC-Related RequestsCompany Plans Prompt Response and Submission of...
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage...
Pesticides. Mycotoxins. Fraudulent Lab Reports. Forged Certificates of Analysis. This Is the State-Licensed Cannabis and Hemp Supply Chain the Courts...
Pesticides. Mycotoxins. Fraudulent Lab Reports. Forged Certificates of Analysis. This Is the State-Licensed Cannabis and Hemp Supply Chain the Courts...
At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA...
At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA...